XTRA:RDC
XTRA:RDCConsumer Retailing

Assessing Redcare Pharmacy (XTRA:RDC) Valuation After Strong 2025 Sales Update

Sales update puts Redcare Pharmacy in focus Redcare Pharmacy (XTRA:RDC) is back on investors’ radar after reporting fourth quarter 2025 group sales of €794 million, compared with €675 million a year earlier, alongside full year sales of €2.9b versus €2.4b in 2024. See our latest analysis for Redcare Pharmacy. Despite the strong sales update, Redcare Pharmacy’s share price has had a weak run, with a 90 day share price return of 24.46% decline and a 1 year total shareholder return of 45.89%...
XTRA:MBG
XTRA:MBGAuto

Is Mercedes-Benz Group (XTRA:MBG) Attractive After Recent Share Price Weakness?

If you are wondering whether Mercedes-Benz Group is attractively priced right now, this article walks through what the current share price really reflects. The stock closed at €58.82, with returns of a 2.6% decline over 7 days, a 1.7% decline over 30 days, a 5.0% decline year to date, a 16.0% return over 1 year, 13.2% over 3 years and 65.6% over 5 years. This gives you a mix of shorter term weakness and longer term gains to think about. Recent coverage around Mercedes-Benz Group has focused...
XTRA:BC8
XTRA:BC8IT

Will AI-Driven Managed Services Shift Bechtle's (XTRA:BC8) Revenue Mix Toward More Resilient Contracts?

Recent coverage indicates that Bechtle AG’s AI-related services are helping drive higher-margin projects and growing recurring managed-service bookings across its European customer base. This shift toward AI-enabled, service-based work highlights how Bechtle may be reshaping its revenue mix toward more resilient, contract-driven income streams. Next, we’ll examine how rising AI-driven, higher-margin managed-service demand could influence Bechtle’s existing investment narrative and risk...
XTRA:RDC
XTRA:RDCConsumer Retailing

How Redcare Pharmacy’s 2025 Sales Surge At Redcare Pharmacy (XTRA:RDC) Has Changed Its Investment Story

Redcare Pharmacy NV recently reported its fourth-quarter 2025 sales of €794 million, up from €675 million a year earlier, with full-year 2025 sales rising to €2.90 billion from €2.40 billion in 2024. This sales expansion underscores how Redcare Pharmacy is scaling its online pharmacy operations across Europe, reinforcing its position in the digital healthcare market. We’ll now examine how this step-up in annual sales reshapes Redcare Pharmacy’s investment narrative, especially around revenue...
XTRA:SZU
XTRA:SZUFood

Will Südzucker's (XTRA:SZU) Return to Quarterly Profit Amid Falling Sales Change Its Risk Narrative?

Südzucker AG has reported past third-quarter 2025 results showing sales of €2,156 million, down from €2,374 million a year earlier, while net income improved to €3 million from a net loss of €119 million and basic loss per share from continuing operations narrowed to €0.02 from €0.62. Over the first nine months, sales fell to €6,355 million from €7,466 million and the company moved from €23 million net income to a €59 million net loss, highlighting that the recent quarterly profit comes...
XTRA:NDX1
XTRA:NDX1Electrical

Assessing Nordex (XTRA:NDX1) Valuation After Fresh Global Wind Turbine Order Wins

Nordex (XTRA:NDX1) has been in focus after securing a series of sizeable turbine orders across Spain, France, Belgium, Portugal, and Canada, many paired with long-term service agreements that extend revenue visibility. See our latest analysis for Nordex. These fresh turbine contracts arrive after a strong run in the stock, with a 90 day share price return of 38.89% and a 1 year total shareholder return of 164.96%, suggesting momentum has recently been building. If Nordex's recent contract...
XTRA:BMW
XTRA:BMWAuto

What Bayerische Motoren Werke (XTRA:BMW)'s China Price Cuts and Buybacks Mean For Shareholders

In early January 2026, Bayerische Motoren Werke AG continued its 2025–2027 share buy-back programme, repurchasing 390,000 ordinary shares across venues such as Xetra and CBOE Europe, with detailed transaction data disclosed on the company’s website. More recently, BMW responded to a 10.4% China sales decline and a much sharper New Energy Vehicle drop by cutting prices on 31 key models by up to 24% and accelerating local partnerships to reinforce its position in the world’s largest auto...
XTRA:FRE
XTRA:FREHealthcare

How Fresenius Kabi’s T Cell Automation Deal At Fresenius SE KGaA (XTRA:FRE) Has Changed Its Investment Story

Earlier this week, Fresenius Kabi and TQ Therapeutics announced a development agreement giving Fresenius Kabi exclusive rights to integrate TQ’s proprietary cell selection technology into its Cue Cell Processing System for automated, high‑purity T cell isolation in cell and gene therapy manufacturing. This collaboration could materially enhance Fresenius’s position in advanced therapies by pairing TQ’s affinity-based cell isolation with Fresenius Kabi’s automation capabilities, potentially...